Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611671 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
A Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- Active
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT05611671 is a Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative that is active but no longer recruiting, run by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). The registered enrollment target is 280 participants, below the 42,256-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05611671, a Phase 2 study of Inflammatory Bowel Diseases and Colitis, Ulcerative, is active but no longer recruiting, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MORF-057
Study Locations (20)
Other
- Blacktown Hospital - Blacktown
- Concord Repatriation General Hospital - Concord
- Royal Brisbane and Women's Hospital - Herston
- Fiona Stanley Hospital - Murdoch
- Mater Adult Hospital Brisbane - South Brisbane
- Order Hospital Linz Ltd. - Hospital of Sisters of Mercy - Linz
- Salzburg Regional Hospital - Salzburg
- Medical University of Vienna - Vienna
- Medical Center "Rusemed" EOOD - Rousse
- University Multiprofile Hospital for Active Treatment "ACIBADEM City Clinic" - Sofia
- Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda - Sofia
- Second Multiprofile Hospital for Active Treatment - Sofia - Sofia
California
- Gastro Care Institute - Lancaster
- TLC Clinical Research Inc. - Los Angeles
Florida
- Innova Clinical Trials - Coral Gables
- Eminat, LLC - Miramar - Miramar
Arizona
- Arizona Digestive Health - Sun City - Sun City
New Jersey
- Robert Wood Johnson University Medical School - New Brunswick
Ohio
- Great Lakes Gastroenterology - Mentor
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05611671
The ClinicalTrials.gov registry entry for NCT05611671 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42,256-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05611671 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05611671 about?
NCT05611671 is a clinical study titled "A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC". This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
What is the current status of trial NCT05611671?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2022-11-21. Estimated completion is 2026-08.
What conditions does trial NCT05611671 study?
This clinical trial studies the following conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative.
What interventions are being tested in trial NCT05611671?
The interventions under investigation include: Placebo (DRUG), MORF-057 (DRUG).
Who is sponsoring clinical trial NCT05611671?
This trial is sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05611671 being conducted?
This trial has 20 study locations across Arizona, California, Florida, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Feasibility Test of Action Planning in Pediatric IBD
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.